Patient‐reported outcomes with risankizumab versus fumaric acid esters in systemic therapy‐naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17109 ◽

2021 ◽

Author(s):

D Thaçi ◽

AM Soliman ◽

K Eyerich ◽

A Pinter ◽

M Sebastian ◽

...

Keyword(s):

Clinical Trial ◽

Fumaric Acid ◽

Plaque Psoriasis ◽

Systemic Therapy ◽

Patient Reported Outcomes ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Patient Reported ◽

Download Full-text

Direct Comparison of Risankizumab and Fumaric Acid Esters in Systemic–Therapy‐Naive Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial

British Journal of Dermatology ◽

10.1111/bjd.20481 ◽

2021 ◽

Author(s):

D. Thaçi ◽

K. Eyerich ◽

A. Pinter ◽

M. Sebastian ◽

K. Unnebrink ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Fumaric Acid ◽

Plaque Psoriasis ◽

Systemic Therapy ◽

Controlled Trial ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Randomized Controlled ◽

Download Full-text

Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial

British Journal of Dermatology ◽

10.1111/bjd.15707 ◽

2017 ◽

Vol 177 (4) ◽

pp. 1024-1032 ◽

Author(s):

M. Sticherling ◽

U. Mrowietz ◽

M. Augustin ◽

D. Thaçi ◽

N. Melzer ◽

...

Keyword(s):

Fumaric Acid ◽

Plaque Psoriasis ◽

Prime Trial ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Randomized Controlled ◽

Systemic Treatments ◽

Download Full-text

A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment

British Journal of Dermatology ◽

10.1111/bjd.18384 ◽

2019 ◽

Vol 182 (4) ◽

pp. 869-879 ◽

Author(s):

K. Reich ◽

M. Augustin ◽

D. Thaçi ◽

A. Pinter ◽

A. Leutz ◽

...

Keyword(s):

Fumaric Acid ◽

Plaque Psoriasis ◽

Systemic Treatment ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Parallel Group Study ◽

Parallel Group ◽

Download Full-text

A phase 4, randomized, head‐to‐head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate‐to‐severe plaque psoriasis (CHANGE)

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.16932 ◽

2020 ◽

Author(s):

A. Pinter ◽

M. Hoffmann ◽

K. Reich ◽

M. Augustin ◽

K. Kaplan ◽

...

Keyword(s):

Fumaric Acid ◽

Plaque Psoriasis ◽

Subcutaneous Injections ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Download Full-text

Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical stud

British Journal of Dermatology ◽

10.1111/bjd.16106 ◽

2018 ◽

Vol 178 (3) ◽

pp. 682-688 ◽

Author(s):

S. Tzaneva ◽

A. Geroldinger ◽

H. Trattner ◽

A. Tanew

Keyword(s):

Fumaric Acid ◽

Plaque Psoriasis ◽

Ultraviolet B ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Download Full-text

Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate‐to‐severe plaque psoriasis naïve to systemic treatment

British Journal of Dermatology ◽

10.1111/bjd.19558 ◽

2020 ◽

Author(s):

A. Leutz ◽

A. Pinter ◽

D. Thaçi ◽

M. Augustin ◽

C. Schuster ◽

...

Keyword(s):

Fumaric Acid ◽

Plaque Psoriasis ◽

Systemic Treatment ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Download Full-text

Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)

British Journal of Dermatology ◽

10.1111/bjd.18696 ◽

2020 ◽

Vol 183 (2) ◽

pp. 265-275 ◽

Author(s):

D. Thaçi ◽

A. Pinter ◽

M. Sebastian ◽

C. Termeer ◽

M. Sticherling ◽

...

Keyword(s):

Fumaric Acid ◽

Plaque Psoriasis ◽

Systemic Treatment ◽

Treatment Results ◽

Active Comparator ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Download Full-text

Efficacy and safety of fumaric acid esters in young patients aged 10 to 17 years with moderate‐to‐severe plaque psoriasis – A randomised, double‐blinded, placebo‐controlled trial

British Journal of Dermatology ◽

10.1111/bjd.19747 ◽

2020 ◽

Author(s):

H. Hamm ◽

D. Wilsmann‐Theis ◽

A. Tsianakas ◽

T. Gambichler ◽

K. Taipale ◽

...

Keyword(s):

Fumaric Acid ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Young Patients ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Double Blinded ◽

Download Full-text

14152 Patient-reported outcomes in a head-to-head, randomized, double-blinded clinical trial of ixekizumab and guselkumab in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.163 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB19

Author(s):

Andrew Blauvelt ◽

Catherine Maari ◽

Alice B. Gottlieb ◽

Hany ElMaraghy ◽

So Young ◽

...

Keyword(s):

Clinical Trial ◽

Plaque Psoriasis ◽

Patient Reported Outcomes ◽

Severe Plaque Psoriasis ◽

Patient Reported ◽

Download Full-text

Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical stud

British Journal of Dermatology ◽

10.1111/bjd.16386 ◽

2018 ◽

Vol 178 (3) ◽

pp. e233-e233

Author(s):

S. Tzaneva ◽

A. Geroldinger ◽

H. Trattner ◽

A. Tanew

Keyword(s):

Fumaric Acid ◽

Plaque Psoriasis ◽

Ultraviolet B ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Download Full-text